The global Cell Lysis & Disruption Market size is expected to reach USD 5.65 billion by 2025 registering a CAGR of 8.31%, according to a new report by Grand View Research, Inc. Demand for cell lysis & disruption is driven by the immense growth of the biotechnology sector globally. This is majorly due to the high adoption of biotech processes in the pharmaceutical, agricultural, and bio-services industries.
Technological
developments in procedures involved to release cellular organelles have paved
the way for higher adoption of cell disruption methods. As retrieval and
purification of biopharmaceuticals involve cell disruption, a rise in demand
for biopharma would lead to the subsequent growth of the market. In addition,
advancements in the field of proteomics, metabolomics, and personalized
medicine are expected to fuel progressive changes in this sector. However, the
high cost of equipment coupled with the dearth of skilled professionals is
expected to restrain revenue generation to a certain extent.
The
restraint can be addressed as the government organizations are releasing
substantial funds to fuel development in the biotechnology sector. Merck KGaA;
Thermo Fisher Scientific, Inc.; Qiagen NV; F. Hoffmann-La Roche Ltd; Becton
Dickinson & Company (BD); Bio-Rad Laboratories, Inc.; Danaher Corporation;
Claremont BioSolutions, LLC; and Miltenyi Biotec GmbH are the prominent
companies in this market. These companies have undertaken strategies, such as
new product development and strategic alliances, to maintain their market
share.
Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/cell-lysis-dissociation-market
Further key findings from the study suggest:
- A rise in
development of biologics has subsequently led to a high demand for better
bioprocess solutions
- The
advantages offered by reagent-based methods for isolation of biological
products is attributive to the largest share of the segment in 2018
- The
advantages include an unaltered biological activity of the sample of
interest and ideal compatibility with the laboratory reagents
- Enzymatic
lysis, owing to higher biological specificity, is anticipated to be the
fastest-growing segment over the forecast period
- Sonication
instruments are expected to witness the maximum CAGR from 2019 to 2025 due
to higher adoption rate of these products due to their reliability
- Mammalian
cell culture systems have grabbed substantial attention among the
biopharmaceutical manufacturers, thus leading to higher demand for cell
lysis protocols for the same
- Academic
research accounted for the largest share in 2018 as a result of higher
usage of cell separation associated protocols in research facilities
- Substantial
research in the development of the nucleic acid-derived products is
expected to drive progress in this application in the coming years
- APAC is
projected to be the fastest-growing regional cell lysis & disruption
market due to lucrative opportunities offered by emerging nations, which
has attracted investments from global firms
About Us:
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, the company offers market intelligence
studies ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment